Presentations
June 2022
EHA 2022: Dose Response Profile of IGM-2323, a CD20xCD3 IgM Bispecific T Cell Engager, in Translational Models Supports Phase 2 Dose Selection in Non-Hodgkin’s Lymphoma
EHA2022 Hybrid Congress – June 9-12, 2022
April 2022
AACR 2022: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas
American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022
April 2022
AACR 2022: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing
American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022
April 2022
AACR 2022: Enhanced NK and CD8+ T cell proliferation, tumor cytotoxicity and reversal of T cell exhaustion with IGM-7354, an anti-PD-L1 IgM antibody and IL-15 cytokine fusion
American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022
April 2022
AACR 2022: Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity
American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022